Novartis Seeks To Block Alleged Infringer Of Votrient Patent In India
Executive Summary
Just months ahead of the patent expiry for Votrient in India, Novartis hauls alleged infringer MSN Laboratories to court, which has bound the Indian firm by its pre-launch assurance for the anticancer therapy.
You may also be interested in...
Natco And MSN Battle Chugai Over Alectinib In India
Roche affiliate Chugai has moved court in India seeking to restrain Natco and MSN Laboratories over alleged infringement of its patent concerning Alecensa. The Indian firms, however, contend their actions fall under the ambit of the country’s “Bolar exemption” provision.
Chugai Pursues Alecensa Patent Infringement Charges In India
Roche affiliate Chugai has moved court in India seeking to restrain Natco and MSN Laboratories over alleged infringement of its patent concerning Alecensa. The Indian firms, however, contend their actions fall under the ambit of the country’s “Bolar exemption” provision.
Alvogen Aims To Be First On EU Pazopanib
Alvogen believes it is the first company to file for a generic pazopanib rival to Novartis’ Votrient oncology brand in Europe.